The Riverside Press-Enterprise
Ebbing of omicron surge is giving global officials hope for manageable future
World health officials are offering hope that the slowing of the omicron wave could give way to a new, more manageable phase of the COVID-19 pandemic, even as they warn of difficult weeks ahead and the possibility of another, more dangerous variant arising.
In the U.S., cases have crested and are dropping rapidly, following a pattern seen in Britain and South Africa, with researchers projecting a period of low spread in many countries by the end of March.
Though U.S. deaths — now at 2,000 each day — are still rising, new hospital admissions have started to fall, and a drop in deaths is expected to follow.
The encouraging trends after two years of coronavirus misery have brought a noticeably hopeful tone from health experts. Rosy predictions have crumbled before, but this time they are backed by what could be called omicron’s silver lining: The highly contagious variant will leave behind extremely high levels of immunity.
On Sunday, Dr. Anthony Fauci talked on ABC “This Week” about a “best-case scenario” where COVID-19 would fall to manageable levels so the United States could get “back to a degree of normality.”
And on Monday, the World Health Organization issued a statement anticipating an end to the “emergency phase” of the pandemic this year and saying that the omicron variant “offers plausible hope for stabilization and normalization.”
Both Fauci and the WHO’S Europe regional director, Dr. Hans Kluge, cautioned that new variants are likely to emerge, but with vaccination, new drug therapies and — during surges — testing and masks, the world could reach a less disruptive level of disease in which the virus is, as Fauci put it, “essentially integrated into the general respiratory infections that we have learned to live with.”
In the U.S., new cases are averaging a still extraordinarily high 680,000 a day, down from an all-time peak of over 800,000 a little more than a week ago.
The places in the U.S. where omicron struck first are seeing the sharpest declines. New cases in the Northeast are nosediving, while other states — Arizona, Texas, Oregon, Kansas and North Dakota among them — are still waiting for relief.
Falling, too, are new U.S. hospital admissions of patients with confirmed COVID-19. They are averaging nearly 20,000 per day, down about 7% from the previous week, according to the Centers for Disease Control and Prevention.
Those numbers include patients who went to the hospital for other reasons and tested positive. But even after accounting for these incidental infections, the trend is hopeful.
One influential model projects that nearly all nations will be past the omicron wave by midmarch, including China and other countries with “zero COVID” policies. The wave will leave behind high levels of immunity — both from infection and vaccination — that could lead to low levels of transmission for many weeks or months.
“What do we end up with at the end of this?” said Dr. Christopher Murray of the University of Washington, who developed the closely watched Institute for Health Metrics and Evaluation model. “We end up with the highest levels of global immunity that we’ve seen in the pandemic.”
The model estimates that 57% of the world’s population already has been infected with the virus at least once.
Another research group, which combines several models and shares the projections with the White House, predicts a strong decline in U.S. infections by April, unless a new variant emerges that can sidestep the growing levels of immunity.
“It would be dangerous to forget that possibility, as it has caught us before,” said Katriona Shea of Pennsylvania State University, a leader of the team that pulls together the models.
She noted, too, that the projections show 16,000 to 98,000 more Americans dying before the omicron wave is through. The U.S. death toll stands at close to 870,000.
“Even if we project a more optimistic future, right now we still have a lot of COVID spreading, a lot of strain in our hospital systems, and our deaths have not yet peaked,” said Lauren Ancel Meyers, director of the University of Texas COVID-19 Modeling Consortium.
“There’s still a lot of pain before omicron has run its course,” she said, but added: “It’s very plausible that omicron will be a turning point in terms of our relationship with this virus.”
Drugs revoked
COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the omicron variant that now accounts for nearly all U.S. infections, U.S. health regulators said Monday.
The Food and Drug Administration said it was revoking emergency authorization for both drugs, which were purchased by the federal government and given to millions of Americans with COVID-19. If the drugs prove effective against future variants, the FDA said it could reauthorize their use.
The regulatory move was expected because both drugmakers had said the infusion drugs are less able to target omicron due to its mutations. Still, the federal action could trigger pushback from some Republican governors who have continued promoting the drugs against the advice of health experts.
Omicron’s resistance to the two leading monoclonal antibody medicines has upended the treatment playbook for COVID-19 in recent weeks.
Doctors have alternate therapies to battle early COVID-19 cases, including two new antiviral pills from Pfizer and Merck, but both are in short supply. An antibody drug from Glaxosmithkline that remains effective also is in short supply.
The drugs are laboratory-made versions of virus-blocking antibodies. They are intended to head off severe disease and death by supplying concentrated doses of one or two antibodies early in an infection. Then-president Donald Trump received Regeneron’s antibody combination after he tested positive for the coronavirus in 2020.
The U.S. government temporarily stopped distributing the two drugs in late December, as omicron was racing across the country to become the dominant variant. But officials resumed distribution after complaints from Republican governors, including Florida’s Ron Desantis, who claimed that the drugs continued to help some omicron patients.
The drugs are not a substitute for vaccination and are generally reserved for people who are the most vulnerable, including seniors, transplant recipients and those with conditions like heart disease and diabetes.